Tromethamine

Tromethamine

SCHEMBL7501623

NC(CO)(CO)CO.O=C(O)[C@H](Cc1ccccc1)Oc1ccc(-c2ccc(-c3c(Cc4ccccc4)oc4ccccc34)cc2)cc1

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA

The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 20/20 0.85
PTPRF P10586 1/20 0.85
PTPRA P18433 1/20 0.85
PTPN7 P35236 1/20 0.85
DUSP3 P51452 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7502934 0.92 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL7498026 0.92 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL4261645 0.92 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL7497974 0.85 PTPN1 (0.81) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL7503127 0.82 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL7500549 0.80 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL7499043 0.80 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL7499865 0.79 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL7510322 0.79 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3
SCHEMBL7503851 0.79 PTPN1 (1.00) PTPN1PTPRFPTPRAPTPN7DUSP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077967-B1 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-12-04 EP claimed
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH 2001-12-20 US claimed
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS 2001-11-15 US claimed
US-6232322-B1 SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT AMERICAN HOME PRODUCTS CORPORATION 2001-05-15 US claimed
EP-1077967-B1 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-12-04 EP disclosed
US-6391897-B2 (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID, FOR EXAMPLE; INHIBIT PROTEIN-TYROSINE PHOSPHATASES (PTPASES) AMERICAN HOME PRODUCTS CORPORATION 2002-05-21 US disclosed
US-6369072-B2 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-04-09 US disclosed
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH 2001-12-20 US disclosed
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS 2001-11-15 US disclosed
US-6232322-B1 SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT AMERICAN HOME PRODUCTS CORPORATION 2001-05-15 US disclosed
EP-1077967-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
WO-1999058518-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP PTPN1 1004/4885PTPRF 1176/4885PTPRA 1115/4885
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP PTPN1 1004/4885PTPRF 1176/4885PTPRA 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.